Evidence map›Paper›PMID 42082628›Full record

ReviewActa pharmacologica Sinica2026

Nanoparticles for autoimmune diseases: advancing diagnostics and therapeutic solutions.

Elaine Xue Ning Ong, Chester Yan Jie Ng, Lu-Lei Cao, Xuexin Li, Pan P Li, Nguan Soon Tan, Zehuan Liao, Yan Zhao

Abstract readReview
In one paragraph

Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elaine Xue Ning Ong *School of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.
Chester Yan Jie Ng *School of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.
Lu-Lei CaoGraduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
Xuexin LiDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, 17165, Sweden.
Pan P LiDepartment of Psychiatry and Behavioral Sciences, Division of Neurobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Nguan Soon TanSchool of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.
Zehuan LiaoSchool of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore. liao0058@e.ntu.edu.sg.
Yan ZhaoSchool of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore. zhaoyan@ntu.edu.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases pose a significant challenge to modern medicine due to their complicated and poorly understood mechanisms, which hinder effective diagnosis and treatment. The rising global incidence of autoimmune disorders is projected to place increasing strain on healthcare systems and financial resources. In response, nanotechnology has emerged as a promising avenue for both the diagnosis and treatment of these conditions. Among various nano-technological approaches, nanoparticles have garnered particular attention due to their advantageous properties including biocompatibility, enhanced drug bioavailability and efficient permeability across biological membranes. Furthermore, their unique characteristics such as magnetic responsiveness, anti-inflammatory, and antimicrobial capabilities, enable precise drug delivery and improved therapeutic outcomes, as well as the potential for earlier disease detection. Despite these promising developments, the clinical translation of nanoparticle-based strategies faces challenges including concerns regarding their stability in vivo and the need for further research to validate their safety and efficacy. While current diagnostic tools remain limited, certain nanoparticles have already received approval from the US Food and Drug Administration, demonstrating their potential for clinical application. This review aims to highlight the recent advances in use of nanoparticles for the diagnosis and treatment of autoimmune diseases, and to explore their prospective role in future clinical practice.

Indexed as

Autoimmune DiseasesNanoparticlesAnimalsDrug Delivery SystemsHumansautoimmune diseasesdiagnostic toolsnanoparticlestherapeutic tools

Identifiers

PMID42082628
PMCPMC13487202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.